Loading...
Loading...
GNLX| Name | Value |
|---|---|
| Revenues | 1,464.0K |
| Cost of Revenue | 201.0K |
| Gross Profit | 1,263.0K |
| Operating Expense | 6,800.0K |
| Operating I/L | -7,001.0K |
| Other Income/Expense | 234.0K |
| Interest Income | 240.0K |
| Pretax | -6,767.0K |
| Income Tax Expense | -4,031.0K |
| Net Income/Loss | -6,767.0K |
Genelux Corporation is a clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for aggressive solid tumors. Its lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus designed for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also working on V2ACT Immunotherapy for pancreatic cancer and V-VET1 for hematologic and solid cancer.
